Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains les...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceglédi, Andrea, Csukly, Zoltán, Fekete, Mónika, Kozma, András, Szemlaky, Zsuzsanna, Andrikovics, Hajnalka, Mikala, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668022/
https://www.ncbi.nlm.nih.gov/pubmed/38025905
http://dx.doi.org/10.3389/pore.2023.1611375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668022/
https://www.ncbi.nlm.nih.gov/pubmed/38025905
http://dx.doi.org/10.3389/pore.2023.1611375

Ejemplares similares